Intellectual Property

NanoSmart has secured intellectual property (IP) rights for key technology patents and associated intellectual property from the inventors: Henry Smith, Ph.D. and James Smith, Ph.D. The controlling patent for this technology has been granted domestically by the U.S. Patent and Trademark Office and internationally under the Patent Cooperation Treaty. In addition, the company has in-licensed technology from Dr. Henry Smith related to preparing stabilized nanoemulsions and other drug delivery platforms. These patents broaden the application of NanoSmart’s tumor-targeting technology and allow expansion into additional indications. 

The Company also relies on unpatented proprietary technologies in the development of its products and also upon the skills, knowledge, and experience of its scientific and technical personnel, as well as those of its advisors, consultants, and other contractors. To help protect the Company's proprietary knowledge that is not patentable, and for inventions for which patents may be difficult to enforce, we use trade secret protections and confidentiality agreements to protect the company's interests.

Application / Patent No.

Title / Description

Status

US 7,799,327

EU 1706145 B1

Autoantibodies utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment

Granted;

Assigned

13/970,099

Antinuclear antibody utilized as a targeting agent for pharmaceutical compounds used in the treatment of cancer and other diseases

Pending;

Assigned

13/374,859

Multi-drug liposomes to treat tumors

Pending;

Licensed

61/796,615

Thermally sensitive nanoemulsion

Pending;

Licensed

© 2020 by NanoSmart Pharmacueticals, Inc.

Terms and Conditions

Privacy Policy